MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Clinical trials for MULTIPLE SCLEROSIS, RELAPSING-REMITTING explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SCLEROSIS, RELAPSING-REMITTING trials appear
Sign up with your email to follow new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug telitacicept tested for MS Flare-Ups
Disease control TerminatedThis phase 2 trial tested telitacicept (RC18) in 8 people with relapsing-remitting multiple sclerosis. The drug aims to reduce relapses by targeting B cells. The study was terminated early, so we have limited data on safety and effectiveness.
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New MS drug trial for japanese patients shows promise but study stopped early
Disease control TerminatedThis study tested the drug natalizumab in 21 Japanese adults with relapsing-remitting multiple sclerosis (MS). The goal was to see if injections under the skin every 4 weeks could reduce new brain lesions over 24 weeks, and to check safety for up to 48 weeks. The study was termin…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC